Table 2. Clinical Characteristics of the Study Population for Real-time PCR Validation Cohort.
| Control cases (n = 37) | SA patients (n = 31) | UA patients (n = 45) | |
| Baseline data | |||
| Sex, M/F | 22/15 | 18/13 | 25/20 |
| Age (yrs) | 59±6 | 62±11 | 63±12 |
| SBP (mm Hg) | 127±15 | 134±22 | 133±15 |
| DBP (mm Hg) | 77±8 | 80±13 | 79±10 |
| BMI (kg/m2) | 26.0±3.4 | 25.6±2.1 | 26.5±3.4 |
| LVEF (%) | 66±11 | 69±7 | 66±7 |
| HR (bpm) | 73±11 | 68±11 | 72±9 |
| hs-CRP (mg/dl) | 1.42 | 1.80 | 1.96 |
| PLT (×1012/L) | 210±58 | 192±47 | 213±50 |
| Glucose (mmol/l) | 4.95±0.70 | 5.82±2.42 | 5.32±0.95 |
| Lipid profile | |||
| LDL cholesterol (mmol/l) | 2.46±0.78 | 2.60±0.76 | 2.66±1.00 |
| HDL cholesterol (mmol/l) | 1.16±0.75 | 1.10±0.50 | 0.96±0.25 |
| TC (mmol/l) | 4.11±0.87 | 4.34±0.92 | 4.18±1.08 |
| Risk factors | |||
| Cigarette smoking, % | 45.9 | 38.7 | 46.7 |
| Hypertension, % | 56.8 | 74.2 | 75.6 |
| Diabetes mellitus, % | 16.2 | 29.0 | 26.7 |
| Hyperlipemia, % | 45.9 | 45.2 | 66.7 |
| Drug Administration | |||
| Statin, % | 48.6 | 51.6 | 42.2 |
| CCB, % | 32.4 | 32.3 | 35.6 |
| Beta-blocker, % | 35.1 | 35.5 | 51.1 |
| Aspirin, % | 35.1 | 51.6 | 53.3 |
| Clopidogrel, % | 27.0 | 45.2 | 28.9 |
| ACEI, % | 16.2 | 19.4 | 24.4 |
| ARB, % | 16.2 | 25.8 | 11.1 |
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LVEF, left ventricular ejection fraction; HR, heart rate; PLT, platelet; CRP, C-reactive protein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TC, total cholesterol; CCB, calcium channel blocker; ACEI, angiotensin-converting enzyme inhibitor; and ARB, angiotensin receptor blocker.